Literature DB >> 33541278

Factors associated with delayed presentation to healthcare facilities for Lassa fever cases, Nigeria 2019: a retrospective cohort study.

Nastassya L Chandra1,2, Hikaru Bolt3, Chioma Dan-Nwafor4, Oladipupo Ipadeola4, Elsie Ilori4, Geoffrey Namara4,5, Adebola T Olayinka4,5, Winifred Ukponu6, Akanimo Iniobong4, Michael Amedu4, Adejoke Akano4, Kachikwulu O Akabike4, Uwaifiokun Okhuarobo7, Stephen Fagbemi8, Emeka Sampson9, Sophie Newitt10, Neville Q Verlander10, Daniel G Bausch3, Olivier le Polain de Waroux3, Chikwe Ihekweazu4.   

Abstract

BACKGROUND: Large outbreaks of Lassa fever (LF) occur annually in Nigeria. The case fatality rate among hospitalised cases is ~ 20%. The antiviral drug ribavirin along with supportive care and rehydration are the recommended treatments but must be administered early (within 6 days of symptom onset) for optimal results. We aimed to identify factors associated with late presentation of LF cases to a healthcare facility to inform interventions.
METHODS: We undertook a retrospective cohort study of all laboratory confirmed LF cases reported in Nigeria from December 2018 to April 2019. We performed descriptive epidemiology and a univariate Cox proportional-hazards regression analysis to investigate the effect of clinical (symptom severity), epidemiological (age, sex, education, occupation, residential State) and exposure (travel, attendance at funeral, exposure to rodents or confirmed case) factors on time to presentation.
RESULTS: Of 389 cases, median presentation time was 6 days (IQR 4-10 days), with 53% attending within 6 days. There were no differences in presentation times by sex but differences were noted by age-group; 60+ year-olds had the longest delays while 13-17 year-olds had the shortest. By sex and age, there were differences seen among the younger ages, with 0-4-year-old females presenting earlier than males (4 days and 73% vs. 10 days and 30%). For 5-12 and 13-17 year-olds, males presented sooner than females (males: 5 days, 65% and 3 days, 85% vs. females: 6 days, 50% and 5 days, 61%, respectively). Presentation times differed across occupations 4.5-9 days and 20-60%, transporters (people who drive informal public transport vehicles) had the longest delays. Other data were limited (41-95% missing). However, the Cox regression showed no factors were statistically associated with longer presentation time.
CONCLUSIONS: Whilst we observed important differences in presentation delays across factors, our sample size was insufficient to show any statistically significant differences that might exist. However, almost half of cases presented after 6 days of onset, highlighting the need for more accurate and complete surveillance data to determine if there is a systemic or specific cause for delays, so to inform, monitor and evaluate public health strategies and improve outcomes.

Entities:  

Keywords:  Delayed presentation; Epidemiology; Healthcare; Lassa fever; Nigeria; Retrospective cohort study; Surveillance

Year:  2021        PMID: 33541278     DOI: 10.1186/s12879-021-05822-4

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  3 in total

1.  Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.

Authors:  Alex P Salam; Alexandre Duvignaud; Marie Jaspard; Denis Malvy; Miles Carroll; Joel Tarning; Piero L Olliaro; Peter W Horby
Journal:  PLoS Negl Trop Dis       Date:  2022-03-30

2.  Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.

Authors:  Laura Merson; Josephine Bourner; Sulaiman Jalloh; Astrid Erber; Alex Paddy Salam; Antoine Flahault; Piero L Olliaro
Journal:  PLoS Negl Trop Dis       Date:  2021-09-21

Review 3.  The One Health approach to incident management of the 2019 Lassa fever outbreak response in Nigeria.

Authors:  Chioma Dan Nwafor; Elsie Ilori; Adebola Olayinka; Chinwe Ochu; Rosemary Olorundare; Edwin Edeh; Tochi Okwor; Oyeronke Oyebanji; Esther Namukose; Winifred Ukponu; Michael Olugbile; Usman Adekanye; Nastassya Chandra; Hikaru Bolt; Geofrey Namara; Oladipupo Ipadeola; Yuki Furuse; Solomon Woldetsadik; Adejoke Akano; Akanimo Iniobong; Michael Amedu; Chimezie Anueyiagu; Lawal Bakare; Anthony Ahumibe; Gbenga Joseph; Chibuzo Eneh; Muhammad Saleh; Naidoo Dhamari; Ihekerenma Okoli; Mairo Kachalla; Rita Okea; Collins Okenyi; Favour Makava; Catherine Makwe; Nkem Ugbogulu; Fritz Fonkeng; Everistus Aniaku; Emmanuel Agogo; Nwando Mba; Olusola Aruna; Patrick Nguku; Chikwe Ihekweazu
Journal:  One Health       Date:  2021-11-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.